A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers

Clinical Pharmacology in Drug Development · Published 2026-01-01 · DOI 10.1002/cpdd.70007

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1002/cpdd.70007

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles